
    
      This is an open-label phase I trial with a 3+3 dose escalation design. All patients will
      receive avelumab, cetuximab, and palbociclib. This study will enroll patients with head and
      neck squamous cell carcinoma not amenable to curative intent therapy.

      Treatment will be administered in 28 day cycles with a pre-defined dose escalation schedule.
    
  